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Purpose. Since long-term patency and device integrity of nitinol stents in SFA lesions are not well studied, we examined
clinical outcome, patency and device integrity after stenting long lesions using a standardized implantation technique.
Methods. Between 2001 and 2006, 59 patients (74 lesions) were treated with the same nitinol self-expandable stent
(Zilver, Cook, USA) and technique for SFA recanalization. Clinical charts and imaging were retrospectively reviewed
for patency (primary and assisted-primary), and device integrity.
Results. Patients were 74.5 (10.9) years old (range 49 to 93), 64% male, 42% diabetic, 62% hypertensive and 67% current
or former smokers. Lesions were 23% TASC B, 16% TASC C, or 61% TASC D. Mean recanalization length was 19 cm
(range 3 to 53). Mean number of stents per patient was 2.8 (total 210). Mean follow-up time was 2.4 years (range 3 days to
4.8 years). Kaplan-Meier estimates for primary patency rates were 90%, 78%, 74%, 69%, and 69% at 1, 2, 3, 4 and 4.8
years, respectively. Ten restenoses at a mean of 500 (388) days (1e1251 days) were successfully recanalized. The assisted
primary patency rates were 96%, 90%, 90%, 90% and 90% at 1, 2, 3, 4 and 5 years, respectively. Six complete occlusions
could not be reverted by a second recanalization procedure, and were treated by surgical bypass (1 case), amputation
(3 cases), or medical management (2 cases). One (1.04%) Class II stent fracture was noted.
Conclusions. SFA recanalization with a standardized implantation technique and nitinol stents provides good long-term
primary and assisted-primary patency.
 2007 Published by Elsevier Ltd on behalf of European Society for Vascular Surgery.
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Lower limb ischemia due to atherosclerotic disease re-
mains a pressing clinical problem without optimal
treatment. Bypass surgery is accepted as definitive,
but morbidity and re-hospitalization rates can be sig-
nificant, with re-operative rates nearing 50%.1 Endo-
vascular treatment of lower limb ischemia with
unassisted balloon angioplasty has shown a disap-
pointing patency rate of 61%, 51% and 48% at 1, 3
and 5 years, respectively.2
Based upon the improved outcomes in coronary le-
sions,3,4 use of stents in treating lower limb lesions has
increased.5,6 However, the clinical outcomes have
*Corresponding author. M. Ferreira, MD, Rua Siqueira Campos,
59/203 Copacabana, Rio de Janeiro, Brazil.
E-mail address: mmvf@uol.com.br1078–5884/000702+ 07 $32.00/0  2007 Published by Elsevier Ltd obeen disappointing in early SFA trials.7e9 Several fac-
tors may influence the outcome of angioplasty and
stenting for lower limb ischemia such as clot forma-
tion, intimal hyperplasia, negative remodeling, recoil,
stent fracture and implantation technique. Technique
variability and device-related problems such as hy-
perplasia and stent fracture have been associated
with restenosis.10 Consequently, prior studies have
not adequately demonstrated that a combination of
consistent technique and use of a reliable stent can
together provide definitive long-term patency.
The stent designs used in the SFA have varied sub-
stantially, including stainless steel balloon-expanded
and nitinol self-expanding stents, covered stents,
drug-eluting stents, and biodegradable stents. Pa-
tency with stainless steel, balloon-expanded stents
was reported at 54% to 80% at 1 year, and 28% at
3 years.11e13 With nitinol, self-expanding stents,
patency was reported to be 75% to 93% at 1 yearn behalf of European Society for Vascular Surgery.
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rupture, stenosis and occlusion with a covered stent,
patency was reported to be 78% at 1 year and 74%
to 87% at 2 years;16,17 however, branch vessels are of-
ten lost when covered. Treating long, calcified occlu-
sions or diffuse tandem lesions with subintimal
angioplasty, patency was reported to be 51% at 6
months.18 Drug-eluting and biodegradable stents re-
main under investigation.
These prior studies suggest that nitinol stents pro-
vide the most promising clinical outcomes, at least
in the short-term. The results, however, vary widely
suggesting that differences between nitinol stents
may be important to clinical outcome.4,10,12 These
prior studies raise questions about the optimal stent
design and the importance of implantation technique.
While some report good short-term results, others re-
port disappointing results.12,19,20 Based upon one
stent design, Greenberg et al.21 suggested that stenting
only increases the cost and not the long-term patency.
However, most of the data are short-term. Few studies
provide results with outcome beyond three years so
the long term results are not well understood; studies
with at least five-year results are needed.
To address this dilemma, we performed a system-
atic retrospective medical chart and imaging review
of patients with lower limb ischemia treated with bal-
loon angioplasty and self-expanding nitinol stents in
femoropopliteal arteries. In treating these patients,
a standardized, consistent technique for implantation
was used and we explored the effect of technique.
One specific stent design was used, and we explored
the integrity of stents implanted in the femoropopli-
teal arteries including above, behind and below the
knee through X-ray imaging to look for strut fractures
in available patients. Follow-up extended up to the
fifth year.
Methods
We performed a retrospective review of medical
charts and imaging for patients treated between
2001 and 2005, to obtain patency rates of the stented
femoropopliteal arterial segment and device integrity.
Since 2001, it has been our practice to indicate primary
angioplasty with stenting to all patients with Ruther-
ford category 2 and above, and no patients have been
referred to primary surgery. During this period, 59
consecutive patients (74 limbs, 210 stents) met the in-
clusion criteria for this retrospective analysis. Patient
selection was based upon the following criteria: 1)
the treated lesion was within the femoropopliteal ar-
tery, including the retropatelar region, 2) includedpatients received only the same model of stents (Zil-
ver, COOK, USA), to exclude a possible influence
from the different fracture, restenosis and occlusion
rates from the different available stent models, 3) in-
cluded patients had incapacitating claudication
(Rutherford category 2 and above), not responsive to
medical therapy for at least 6 months.
During the past five years, we have treated 121 pa-
tients that met the clinical criteria; however, most of
these patients had different stent models within the
same vessel, sometimes overlapping. This occurred
mainly in those patients treated within the early years.
We observed that the results were influenced by this,
and justified selecting only those patients with one
single model of stent. The selected model was the
one we used most frequently, for two main reasons:
1) it is widely available and has good cost-effectiveness.
This is crucial as the stents were paid by private med-
ical insurance companies, and 2) we observed appar-
ently good results with the selected model during the
years of practice.
The diagnosis of obstructive arterial disease was
confirmed largely by clinical history and duplex ultra-
sound examinations, performed pre-operatively.
Diagnostic angiography was not considered necessary
before the treatment procedure if the duplex ultra-
sound examination was adequate.
Because outcome is dependent upon technique, we
adopted a standardized technique for recanalization
of the femoropopliteal artery. The standardized tech-
nique is summarized in Table 1. Briefly, a contralateral
approach to femoral access was chosen to isolate po-
tential access complications, such as thrombotic occlu-
sion or debris related to the percutaneous closure
devices, from affecting the treated artery. Moreover,
contralateral access allowed treatment of dissections
or stenotic lesions proximal to the intended treatment
site that are unappreciated pre-procedure. A hydro-
philic wire guide and mammary catheter were ad-
vanced to reach the femoral bifurcation on the
contralateral side. After exchanging the wire guide
to a stiff wire guide, a long and flexible sheath was
gently advanced into the common iliac as a worksta-
tion platform. This was important to provide support
for advancement through the stenotic, and more im-
portantly the occluded vessels. After wire exchange
to a short tip hydrophilic wire, a mammary (or verte-
bral) catheter was advanced through the stenosed or
obstructed femoropopliteal artery until the true lu-
men of the distal popliteal artery was reached. In sev-
eral cases, but not all cases, the wire and catheter
became subintimal and the wire guide was rotated
to re-enter the true lumen at least by the end of the
lesion. After exchanging to a stiff wire guide,Eur J Vasc Endovasc Surg Vol 34, December 2007
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10 cm in a small diameter popliteal), was advanced
into the lesion and the vessel was pre-dilated at 8 to
10 atmospheres for 3 minutes. Following initial bal-
loon angioplasty, self-expanding nitinol stents (Zilver,
COOK, USA) were implanted to cover the entire di-
lated segment. The stents were submitted to a post-di-
latation. When more than one stent was needed to
cover the lesion, the most distal stents were placed
first and adjacent stents were overlapped by 10 mm
to avoid interstent focal stenosis due to unstented ves-
sel recoil, flow disturbance or stent misalignment. Fi-
nal angiograms were taken after wire guide removal
to document patency. After the procedure, patients
were treated with aspirin (300 mg QD) indefinitely,
and clopidogrel (75 mg QD) for at least six months,
to prevent clot formation.
During follow-up, patients were assessed for clini-
cal outcome, image-based patency and stent integrity.
The diagnosis of obstructive arterial disease post-
operatively was confirmed largely by duplex ultra-
sound examination, performed at 6 month intervals
after recanalization or at the presentation of post-
operative symptoms. When the duplex ultrasound
Table 1. Standardized Recanalization Technique
SFA Recanalization Technique
1 Via contralateral retrograde femoral access, advance a 100 cm
mammary beacon tip catheter (HNBR, COOK) over a hydrophilic
wire guide (0.035 260 Road Runner, COOK, USA) to the femoral
bifurcation proximal to the lesion.
2 Exchange the wire guide to a stiff wire (0.035 260 Amplatz Stiff
Wire Guide, COOK, USA) and sheath to a 70 cm long 6F sheath
(6F 55, 70, or 90 Flexor Raabe Sheath, COOK, USA), and gently
advance the sheath over the wire to the common femoral artery.
3 Exchange the wire to a short taper hydrophilic wire guide
(.035 260 Roadrunner RPC, COOK, USA), and exchange the
dilator for the mammary catheter and gently advance the
mammary catheter and wire into the obstructed SFA, until the
true lumen of the distal popliteal artery is reached, sometimes but
not always passing through a sub-intimal path.
4 Exchange the wire guide to the stiff wire, and advance the sheath
into the SFA.
5 Exchange the mammary catheter for a 4 mm 10 cm or
6 mm 10 cm balloon (Pursuit Balloon Catheter, COOK, USA),
advance the balloon catheter to the lesion and inflate to 8 atm for 3
minutes. For lesions longer than the balloon, inflations were
repeated as necessary.
6 Over the same wire guide, the entire length of the dilated segment
of the artery is then covered with self-expanding nitinol stents
(Zilver, COOK, USA). If multiple stents are required to cover the
dilated segment, overlap stents by at least 5 to 10 mm.
7 After an angiographic control, as necessary, the stent is post-
dilated within its margins with a new balloon.
8 A percutaneous closure device is used to close the contralateral
femoral artery.
9 During follow-up, patients are treated with acetyl salicylic acid,
300 mg per day, continuously, and 75 mg daily clopidogrel, for at
least six months, to prevent clot formation.
10 A control duplex ultrasound exam is performed before hospital
discharge and every six months.
Eur J Vasc Endovasc Surg Vol 34, December 2007exam indicated restenosis of >50% or occlusion, a sec-
ond recanalization procedure using angioplasty was
considered when a 50% or higher stenosis was evi-
dent on the angiogram. If the second recanalization
was successful, the result was considered an assisted-
primary patency, but not a primary patency.
Standard X-ray flat films were not sufficient in most
cases for detailed examination of the stent struts for
evaluating device integrity. Therefore, available pa-
tients underwent additional good resolution X-rays
adjusted to specifically highlight stent structure. All ef-
forts were made to obtain unobstructed images free of
bone artifact of each implanted stent. However, at the
time of this retrospective analysis no X-rays were avail-
able for 11 patients (41 stents) that had died prior to
having a good resolution X-ray, and for 21 patients
(59 stents) that did not return for an X-ray either be-
cause the patient chose not to or was unable to return,
or our staff was unable to contact the patient in suffi-
cient time to be includedwithin this analysis, or the pa-
tient was lost to follow-up. Additionally, eight of the 27
patients with good resolution X-rays had at least one
stent that was unable to be assessed. Of these eight pa-
tients, 14 stents could not be assessed because: 9 stents
had a complete overlap within another stent; 3 stent X-
rays were disqualified because of bone artifact and
poor resolution, one stent was superimposed over
bone on the X-ray, and one stent X-ray was of poor res-
olution. All of these factors prevent proper strut by
strut analysis; however, all available X-rays were as-
sessed for type IV fracture. Each evaluable image
was examined for broken struts.
All patients treated in our practice for lower limb
ischemia were screened for the inclusion criteria and
patients meeting the criteria were identified. The clin-
ical outcome, imaging and device integrity data were
obtained from a retrospective review of clinical charts
and images. The data were maintained in a de-identified
database. With the de-identification of retrospective chart
data, individual informed consent was not required.
Statistical analysis
Continuous data were provided as mean and stan-
dard deviation (in parenthesis). Dicotomous variables
were listed in percent. Survival and patency rates (pri-
mary and assisted primary) are presented as plots of
Kaplan-Meier estimates. All statistical analyses were
performed using SAS (version 8.2).
Results
Patient demographics showed that 64% were male,
42% were diabetic, 62% had hypertension and 67%
705SFA Recanalization with Self-expanding Stentswere current or former smokers (Table 2). The mean
age was 74.5 (10.9) years and the range was 49 years
to 93 years. By Rutherford classification, the 59 pa-
tients were 22% Category 2, 63% Category 3, and
15% Category 4 or greater. There were 74 lesions
[mean length¼ 19.2 cm (10.8 cm)] with a range of 3
to 53. Lesion classification was notably higher than
in other studies with nearly 80% of patients having
at least one class C or D lesion, and by lesion (limb)
23% were TASC B, 16% were TASC C, and 61%
were TASC D. All patients selected received only
one kind of stent (Zilver, COOK, USA), and patients
with different stent models in the same vessel were
excluded. A total of 210 Zilver stents was used in
the 59 selected patients (74 limbs). The mean number
of stents implanted per lesion was 2.8 (1.6) stents
(range, 1 to 8 stents).
The implant results demonstrated successful recan-
alization for all treated lesions (100% technical suc-
cess), although 2 cases required retrograde access
from the popliteal artery under duplex scan guidance.
There were no failures to access the lesion, deploy the
stents, or achieve patency at the end of the procedure.
However, extension or compression of cells of the
stent during deployment was noted under detailed
examination for some patients and felt to be associ-
ated with movement of the delivery system handle
during retraction of the outer sheath to release the
stent.
Table 2. Baseline Patient Characteristics
Characteristic
Age (years)
Mean S.D. 74.5 10.9
Range (49e93)
Gender (% male) 64.4
Rutherford Category
1 0.0%
2 22.0%
3 62.7%
4 5.1%
5 6.9%
6 3.4%
Claudication (%) 97.8
Hypertension (%) 62.3
Hypercholesterolemia (%) 38.5
Diabetes Mellitus (%) 41.5
MI (%) 36.0
CHF (%) 36.0
Carotid Disease (%) 21.2
Renal Disease (%) 20.8
Pulmonary Disease (%) 19.2
Smoking Status (%)
Current 11.5
Quit 55.8
Never 23.1
Unknown 9.6The mean follow-up time was 29 (16) months
(range 3 days to 58 months), and 58% of patients
were followed for more than 2 years. The survival
rates were 90%, 86%, 80%, 72%, and 64% at 1, 2, 3, 4
and 4.8 years, respectively (Fig. 1). Thirteen patients
died after treatment. Three patients died within 30
days after surgery due to sudden death, pneumonia
with multiple organ failure, and MI during dialysis
for pre-existing renal insufficiency. Of the other 10
cases of death, 3 died within 31e180 days, none
died within 6 months to 1 year, 2 died within 1 to 2
years, 2 died within 2 to 3 years, 2 died within 3 to
4 years, and 1 died within 4 to 4.8 years. Of the 13
patients, 11 patients maintained primary patency or
assisted-primary patency in the last follow-up exam
before death. However, one of the 11 patients died
one day after the secondary procedure to maintain
patency. Of the two patients that died without limb
patency, one patient required amputation (died
1-month post-amputation) and one patient required
bypass (died >2 years post-bypass).
During follow-up, there were 16 cases of restenosis
(10 cases) or complete occlusion (6 cases). Of these 16
cases, 2 occurred within 30 days, 4 within 31e180
days, 1 within 6 months to 1 year, 5 within 1 to 2
years, 2 within 2 to 3 years and 1 within 3 to 4 years.
There was one case of acute occlusion, occurring on
post-operative day 2 (amputation was required). The
primary patency rates were 90%, 78%, 74%, 69% and
69% at 1, 2, 3, 4 and 4.8 years, respectively (Fig. 2).
There have been no reports of loss of patency beyond
4 years of follow-up. The assisted-primary patency
rates were 96%, 90%, 90%, 90% and 90% at 1, 2, 3, 4
and 4.8 years, respectively (Fig. 3). Treatment failure,
represented by an occlusion not treatable with an
Fig. 1. Freedom from Death e 13 patients died during the
time of the study.
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of limbs). These failures occurred at 2, 50, 161, 392, 454
and 537 days post-implant.
Each evaluable image was examined for abnormal
stent deployment, broken struts and complete trans-
sectional fracture. Of 96 stents with good resolution
X-ray films, abnormal stent deployment was noted
in 4 stents, and Class II (multiple single struts at dif-
ferent locations) fracture was noted in 1 stent (1%)
(Fig. 4). No Class I (single strut), Class III (multiple
strut fractures resulting in complete transaction of
the stent) or Class IV (complete transaction of the
stent and the two pieces of the stent separate from
one another or spiral fracture) fractures were ob-
served. Regarding only Class IV, 110 stents could be
evaluated and none presented this type of fracture.
Fig. 2. Cumulative Primary Patency rates.
Fig. 3. Cumulative Assisted-Primary Patency rates.
Eur J Vasc Endovasc Surg Vol 34, December 2007Discussion
Our results corroborate growing literature suggesting
that stenting of the femoropopliteal arterial segment
can be safe and effective if the stent design and
implantation techniques are appropriate.10e13,15,16 In
our opinion, the stent design in this study apparently
did not exhibit a propensity for stent fracture and the
details of the implantation technique were found to be
important to longer term treatment success.
Our study confirmed that the stent design and
treatment strategies must be adapted to the femoro-
popliteal arterial segment, such as the need for longer
stents. While it seems reasonable to expect coronary-
like results also in the femoropopliteal arterial seg-
ment, the femoropopliteal arterial segment lesion
present a more complex situation. It is now widely
accepted that the femoropopliteal arterial segment
lesions are longer and subject to more stretching,
twisting, bending and compression.22 The extensive
plaque is often intermittently calcified presenting the
risk of further plaque rupture after intervention.
Restenosis, occlusion and fracture rates have been di-
rectly related to mechanical factors such as material
and design of stents, as well as its physical character-
istics, markedly its radial force and flexibility.22 The
Fig. 4. Class II stent fracture e Multiple single struts at
different locations.
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cific design with strong radial force, flexibility and
appropriate intra-strut spacing, probably responsible
for a share of the good technical results. Appropriate
intra-strut spacing provides spacing close enough to
support vessel plaque flaps reducing restenosis but
open enough to allow blood flow through small
branch arteries, as seen in the control intra-operative
angiography.
Early trials of nitinol stents in the femoropopliteal
arterial segment reported stent fracture in 32% of
limbs treated with the nitinol stents.10 Patency at 12
months was reduced from 84.3% to 41.1% in lesions
with fractured stents.10 While the direct relationship
between stent fracture and patency remains contro-
versial, we did not experience the high fracture rate
and the 12-month patency rate was excellent at 90%
even with near 80% TASC C and D lesions.
Schlager et al.12 evaluated restenosis, clinical deterio-
ration and fracture rates betweenWallstents (Boston Sci-
entific, USA) and two different nitinol self-expandable
stents, the SMART (Cordis, USA) and the Dynalink/
Absolute (Guidant, USA). For patency and clinical dete-
rioration, results were favorable for nitinol stents com-
pared to the Wallstent. However, regarding stent
fracture, the SMART stent fracture rate of 28% was sig-
nificantly higher than the 2% rate for Dynalink/Abso-
lute and fracture of the SMART stent was associated
with restenosis. Comparing the Schlager et al.12 study
with our series, patients in the Schlager et al.12 study
were younger (67 vs. 74 years) and had a shorter
mean lesion length (10 cm vs. 19 cm), yet the patency
rates at 3 years were 47% and 51% for SMART and
Dynalink, respectively, versus 74% in our series using
Zilver stents.
Schillinger et al.20 reported a 2% fracture at 1 year in
a nitinol stent (Dynalink) used in the femoropopliteal
artery. Our results also indicate that a nitinol stent
(Zilver) can be implanted in the femoropopliteal arte-
rial segment without high fracture rates up to 4.8
years. Not all stents in our series had a good resolu-
tion stent X-ray for evaluation, and we recognize
this as a limitation of the study. However, all patients
were evaluated for clinical outcome. Thus, if stent
fracture is somehow related to patency the good clin-
ical outcome in our series provides further support for
a low fracture rate.
Previous studies showed angioplasty success rates
in the SFA around 40% of patients remaining asymp-
tomatic after four years, and yet keeping the possibil-
ity of an endovascular re-intervention in about 50% of
the patients with primary failure.2 Predictors of
immediate failure were found to be advanced age
and final angioplasty quality, represented by residualstenosis or dissection. Final angioplasty quality was
also a significant factor in long-term restenosis and
occlusion.2,23
In our series, final angiographic quality was con-
sidered very important and efforts to optimize final
angiographic results included angioplasty and stent
coverage of the complete lesion including coverage
of areas with threatening, but not tightly stenosed pla-
que such as the vessel segment between two serial ste-
noses. This resulted in longer recanalization lengths,
post-stent dilatation within the stent for optimal ex-
pansion, and the use of more nitinol self-expandable
stents. We believe that the selective use of stents
only in residual stenoses remaining after angioplasty
allows vessel recoil between stents reducing long-
term patency. Although it is recognized that the use
of more stents will increase the procedure cost, how-
ever, the cost of stents is decreasing, the hospital stay
is shorter than open bypass surgery, and improved
clinical outcome should reduce the re-intervention
rates, offsetting the cost.
The experience in treating SFA by conventional sur-
gery has taught us that atherosclerotic plaques are
actually longer than the length localized by angiogra-
phy. It is well known that serial lesions have higher
restenosis rates. Therefore, long recanalization with
stents avoids a potential fracture in the plaques and
the related inflammatory reaction between adjacent
stenotic segments.
Monitoring patency is also important. Clinical
follow-up and duplex ultrasound exams were per-
formed at six month intervals to identify restenosis
and we re-intervened when indicated to optimize
patency often before the patient became symptomatic
or the vessel became totally occluded which would
make the re-intervention more difficult. Consequently,
the assisted-primary patency rates (endovascular re-
intervention, but not open surgical bypass) were
excellent out to near five years. Anti-platelet and anti-
coagulants are also invaluable for maintaining pa-
tency, and therefore, methods to improve patient
compliance are valuable.
Our experience with the SFA recanalization tech-
nique was very satisfactory, with long-term patency
rates similar to those we achieved in our experience
with femoropopliteal bypasses, without some unde-
sirable complications seen with conventional surgery,
such as infection of operative site or skin necrosis. In
a few cases with complications, retrospectively,
improved patient selection may have reduced the
number of patients requiring amputation.
The TASC consensus recommendation that angio-
plasty is first choice for Classes A and B, but not for
Class C and D lesions could be challenged by the
Eur J Vasc Endovasc Surg Vol 34, December 2007
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The percent of patients with at least one TASC C or
D lesion comprised nearly 80% of our cohort. In the
cases included in this study, the same technique was
used independent of the TASC lesion classification.
The only exception may be that the TASC C and D le-
sions required longer recanalization and more stents.
While skepticism around the SFA angioplasty still
exists, continued improvements in endovascular de-
vices and techniques may yield results similar to
open bypass surgery without the morbidity. Our
own daily experience has shown invaluable benefits
and satisfaction to our patients, a reason why it has
become our first choice for the treatment of inferior
limb obstructive disease. We consider the SFA recana-
lization technique a safe and efficient treatment for in-
ferior limb obstructive disease.
In summary, this study demonstrates the safety
and effectiveness of stenting in the femoropopliteal
arterial segment when nitinol self-expanding stent,
a standardized implantation technique and periodic
clinical follow-up are utilized. To corroborate these
findings or compare these findings against other ther-
apies or devices, a larger randomized clinical study is
recommended.
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